Polyglutamine Diseases and Neurodegeneration: The Example of Ataxin-1
A family of nine human neurodegenerative diseases is caused by anomalous expansion of polyglutamine (polyQ) tracts in the carrier proteins. Understanding the cellular and molecular mechanisms which lead to disease is essential both for understanding these pathologies and for designing appropriate diagnostics. We review here, as a paradigmatic example, the knowledge accumulated for ataxin-1, the protein responsible for Spinocerebellar Ataxia type 1 (SCA1) and one of the smallest representatives of the polyQ family. It appears clear from this overview that understanding the properties and the interaction networks formed by both expanded and non-expanded ataxin-1 is an essential step for our comprehension of the non-pathologic function of the protein and of its role in disease. A better understanding will be reached in the future from integrating knowledge arising from different fields.
KeywordsAtaxin-1 SCA1 Neurodegenerative disease Polyglutamine CAG triplet AXH ULM Molecular switch Transcriptional repression RNA processing Protein context
We would like to thank Rajesh P. Menon and Paola Giunti for helpful comments.
- Al-Ramahi, I., Lam, Y.C., Chen, H.K., de Gouyon, B., Zhang, M., Perez, A.M., Branco, J., de Haro, M., Patterson, C., Zoghbi, H.Y. et al. (2006) CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 281: 26714–26724.PubMedCrossRefGoogle Scholar
- Bowman, A.B., Lam, Y.C., Jafar-Nejad, P., Chen, H.K., Richman, R., Samaco, R.C., Fryer, J.D., Kahle, J.J., Orr, H.T. and Zoghbi, H.Y. (2007) Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat. Genet. 39: 373–379.PubMedCrossRefGoogle Scholar
- Chen, H.K., Fernandez-Funez, P., Acevedo, S.F., Lam, Y.C., Kaytor, M.D., Fernandez, M.H., Aitken, A., Skoulakis, E.M., Orr, H.T., Botas, J. et al. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113: 457–468.PubMedCrossRefGoogle Scholar
- Cummings, C.J., Reinstein, E., Sun, Y., Antalffy, B., Jiang, Y., Ciechanover, A., Orr, H.T., Beaudet, A.L. and Zoghbi, H.Y. (1999) Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24: 879–892.PubMedCrossRefGoogle Scholar
- Genis, D., Matilla, T., Volpini, V., Rosell, J., Davalos, A., Ferrer, I., Molins, A. and Estivill, X. (1995) Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)n expansion and early premonitory signs and symptoms. Neurology 45: 24–30.PubMedGoogle Scholar
- Jodice, C., Malaspina, P., Persichetti, F., Novelletto, A., Spadaro, M., Giunti, P., Morocutti, C., Terrenato, L., Harding, A.E. and Frontali, M. (1994) Effect of trinucleotide repeat length and parental sex on phenotypic variation in spinocerebellar ataxia I. Am. J. Hum. Genet. 54: 959–965.PubMedGoogle Scholar
- Tsai, C.C., Kao, H.Y., Mitzutani, A., Banayo, E., Rajan, H., McKeown, M. and Evans, R.M. (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 101: 4047–4052.PubMedCrossRefGoogle Scholar
- Zoghbi, H.Y. and Orr, H.T. (2009) Pathogenic mechanisms of a polyglutamine mediated neurodegenerative disease: SCA1. J. Biol. Chem. 284: 7425–1749.Google Scholar